NRAS overexpression
|
Uveal Melanoma
|
NRAS overexpression
|
Uveal Melanoma
|
selumetinib Resistant: C3 – Early Trials
|
selumetinib Resistant: C3 – Early Trials
|
NRAS overexpression
|
Melanoma
|
NRAS overexpression
|
Melanoma
|
vemurafenib Resistant: C3 – Early Trials
|
vemurafenib Resistant: C3 – Early Trials
|
NRAS overexpression
|
CRC
|
NRAS overexpression
|
CRC
|
cetuximab + vemurafenib Resistant: D – Preclinical
|
cetuximab + vemurafenib Resistant: D – Preclinical
|
NRAS overexpression
|
Melanoma
|
NRAS overexpression
|
Melanoma
|
DEL-22379 Sensitive: D – Preclinical
|
DEL-22379 Sensitive: D – Preclinical
|